Neural Therapeutics Inc. (CSE:NURL)
0.0250
+0.0050 (25.00%)
At close: Dec 5, 2025
Neural Therapeutics Company Description
Neural Therapeutics Inc., an ethnobotanical drug discovery and development company, develops over-the-counter dietary supplements and psychedelic-based therapeutic drugs to treat mental illnesses in Canada.
The company utilizes psychoactive plants, such as San Pedro, a cactus containing mescaline, for the creation of plant-based traditional medicine.
Its products target substance use disorders, including alcohol and opioid dependence. The company was formerly known as Psychedelic Science Corp. and changed its name to Neural Therapeutics Inc. in November 2021.
Neural Therapeutics Inc. was founded in 2020 and is headquartered in Toronto, Canada.
Neural Therapeutics Inc.
| Country | Canada |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Ian Campbell |
Contact Details
Address: 130 Adelaide Street West Toronto, Ontario M5H 3P5 Canada | |
| Phone | 647-697-6875 |
| Website | neuraltherapeutics.ca |
Stock Details
| Ticker Symbol | NURL |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ian Campbell | Chief Executive Officer |
| Omar Gonzalez | Chief Financial Officer |